Regeneron Pharmaceuticals Inc. buy Piper Sandler
Summary
This prediction is currently active. With a performance of -2.27%, the BUY prediction by Piper_Sandler is trending in the wrong direction. This prediction currently runs until 31.03.27. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | -0.954% |
| iShares Core DAX® | 3,01 % |
| iShares Nasdaq 100 | 3,01 % |
| iShares Nikkei 225® | 4,14 % |
| iShares S&P 500 | 2,38 % |
Comments by Piper_Sandler for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Piper_Sandler for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
27.01.25
27.01.26
28.01.26
Regeneron Pharmaceuticals Inc.
01.11.24
01.11.25
02.11.25
Regeneron Pharmaceuticals Inc.
23.08.24
23.08.25
24.08.25

